JP2018506983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506983A5 JP2018506983A5 JP2017545941A JP2017545941A JP2018506983A5 JP 2018506983 A5 JP2018506983 A5 JP 2018506983A5 JP 2017545941 A JP2017545941 A JP 2017545941A JP 2017545941 A JP2017545941 A JP 2017545941A JP 2018506983 A5 JP2018506983 A5 JP 2018506983A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- retroviral
- vector
- mitogenic
- lentiviral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims description 50
- 210000004027 cell Anatomy 0.000 claims description 45
- 230000001177 retroviral effect Effects 0.000 claims description 37
- 108091005703 transmembrane proteins Proteins 0.000 claims description 34
- 102000035160 transmembrane proteins Human genes 0.000 claims description 34
- 230000002297 mitogenic effect Effects 0.000 claims description 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 24
- 239000013603 viral vector Substances 0.000 claims description 22
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 20
- 230000006044 T cell activation Effects 0.000 claims description 16
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 13
- 108090000695 Cytokines Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 238000004806 packaging method and process Methods 0.000 claims description 11
- 229960002685 biotin Drugs 0.000 claims description 10
- 235000020958 biotin Nutrition 0.000 claims description 10
- 239000011616 biotin Substances 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 9
- 108010090804 Streptavidin Proteins 0.000 claims description 8
- 108700004030 rev Genes Proteins 0.000 claims description 6
- 241001430294 unidentified retrovirus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 101150098213 rev gene Proteins 0.000 claims description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 101710121417 Envelope glycoprotein Proteins 0.000 claims description 4
- 241000713813 Gibbon ape leukemia virus Species 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100021696 Syncytin-1 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 210000004779 membrane envelope Anatomy 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 230000002463 transducing effect Effects 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 2
- 102000003812 Interleukin-15 Human genes 0.000 claims description 2
- 108090000172 Interleukin-15 Proteins 0.000 claims description 2
- 201000005505 Measles Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 241001504519 Papio ursinus Species 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 230000009261 transgenic effect Effects 0.000 claims description 2
- 241000713666 Lentivirus Species 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108700004026 gag Genes Proteins 0.000 claims 1
- 108700004029 pol Genes Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 102000004473 OX40 Ligand Human genes 0.000 description 1
- 108010042215 OX40 Ligand Proteins 0.000 description 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503500A GB201503500D0 (en) | 2015-03-02 | 2015-03-02 | Cell |
| GB1503500.9 | 2015-03-02 | ||
| PCT/GB2016/050537 WO2016139463A1 (en) | 2015-03-02 | 2016-03-01 | Retroviral and lentiviral vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020050861A Division JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506983A JP2018506983A (ja) | 2018-03-15 |
| JP2018506983A5 true JP2018506983A5 (https=) | 2019-01-24 |
| JP6695347B2 JP6695347B2 (ja) | 2020-05-20 |
Family
ID=52876362
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545941A Active JP6695347B2 (ja) | 2015-03-02 | 2016-03-01 | レトロウイルスおよびレンチウイルスベクター |
| JP2020050861A Withdrawn JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
| JP2023029559A Withdrawn JP2023060000A (ja) | 2015-03-02 | 2023-02-28 | レトロウイルスおよびレンチウイルスベクター |
| JP2025227149A Pending JP2026026312A (ja) | 2015-03-02 | 2025-12-03 | レトロウイルスおよびレンチウイルスベクター |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020050861A Withdrawn JP2020092722A (ja) | 2015-03-02 | 2020-03-23 | レトロウイルスおよびレンチウイルスベクター |
| JP2023029559A Withdrawn JP2023060000A (ja) | 2015-03-02 | 2023-02-28 | レトロウイルスおよびレンチウイルスベクター |
| JP2025227149A Pending JP2026026312A (ja) | 2015-03-02 | 2025-12-03 | レトロウイルスおよびレンチウイルスベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US10954530B2 (https=) |
| EP (2) | EP3904523A1 (https=) |
| JP (4) | JP6695347B2 (https=) |
| KR (1) | KR20180002602A (https=) |
| CN (1) | CN107406860A (https=) |
| AU (1) | AU2016227474A1 (https=) |
| BR (1) | BR112017018251A2 (https=) |
| CA (1) | CA2977472A1 (https=) |
| CL (1) | CL2017002199A1 (https=) |
| ES (1) | ES2877398T5 (https=) |
| GB (1) | GB201503500D0 (https=) |
| IL (1) | IL253820B (https=) |
| MX (1) | MX2017010553A (https=) |
| RU (1) | RU2017133854A (https=) |
| SG (1) | SG11201706721PA (https=) |
| WO (1) | WO2016139463A1 (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035875T2 (hu) | 2013-10-25 | 2018-06-28 | Psioxus Therapeutics Ltd | Heterológ géneket tartalmazó onkolitikus adenovírusok |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| KR101697473B1 (ko) | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| HRP20200439T1 (hr) | 2015-04-30 | 2020-06-12 | Psioxus Therapeutics Limited | Onkolitički adenovirus koji kodira protein b7 |
| US10046317B2 (en) * | 2015-08-11 | 2018-08-14 | Chevron U.S.A. Inc. | Middle distillate hydrocracking catalyst containing zeolite beta with low OD acidity and large domain size |
| EP3365453A2 (en) | 2015-10-22 | 2018-08-29 | Juno Therapeutics GmbH | Methods, kits, agents and apparatuses for transduction |
| BR112018012180A2 (pt) | 2015-12-17 | 2018-12-04 | Psioxus Therapeutics Ltd | vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr |
| CU24649B1 (es) * | 2016-03-19 | 2023-02-13 | Exuma Biotech Corp | Retrovirus recombinantes incompetentes de replicación para la transducción de linfocitos y expansión regulada de los mismos |
| US11325948B2 (en) | 2016-03-19 | 2022-05-10 | Exuma Biotech Corp. | Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL |
| US11111505B2 (en) | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| US12590321B2 (en) | 2016-03-19 | 2026-03-31 | Exuma Biotech Corp. | Methods and compositions for genetically modifying and expanding lymphocytes and regulating the activity thereof |
| GB201614093D0 (en) | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| IL303187A (en) | 2016-08-29 | 2023-07-01 | Akamis Bio Ltd | Adenovirus with bispecific T cell activator |
| KR20190098747A (ko) * | 2016-12-05 | 2019-08-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 치료법을 위한 조작된 세포의 제조방법 |
| WO2018120843A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海近岸生物科技有限公司 | 一种三功能分子及其应用 |
| WO2018120842A1 (zh) * | 2016-12-30 | 2018-07-05 | 上海欣百诺生物科技有限公司 | 一种双功能分子及其应用 |
| KR102879522B1 (ko) * | 2017-03-03 | 2025-11-04 | 엑수마 바이오테크, 코포레이션 | 림프구를 형질도입 및 팽창시키고 이들의 활성을 조절하기 위한 방법 및 조성물 |
| EP3633029A4 (en) * | 2017-05-26 | 2021-06-09 | Green Cross Lab Cell Corporation | METHOD OF DEVELOPING A NATURAL KILLER CELL USING A T-CELL |
| EP3735460A4 (en) * | 2017-09-18 | 2021-08-11 | Exuma Biotech Corp. | METHODS AND COMPOSITIONS FOR THE GENETIC MODIFICATION AND EXPANSION OF LYMPHOCYTES AND THE REGULATION OF THE ACTIVITY OF THE LATTER |
| US11957715B2 (en) * | 2017-12-20 | 2024-04-16 | Miltenyi Biotec B.V. & Co. KG | Method for NK cell transduction |
| CA3096458A1 (en) | 2018-04-12 | 2019-10-17 | Umoja Biopharma, Inc. | Viral vectors and packaging cell lines |
| CN112567025B (zh) * | 2018-08-10 | 2025-01-17 | 国立大学法人京都大学 | Cd3阳性细胞的制造方法 |
| CN113840911A (zh) * | 2018-09-02 | 2021-12-24 | 埃克苏马生物技术公司 | 用于在血液中或在富集pbmc中基因修饰淋巴细胞的方法和组合物 |
| AU2019381526B2 (en) | 2018-11-14 | 2023-02-23 | Green Cross Lab Cell Corporation | Method for culturing cord blood-derived natural killer cells using transformed T-cells |
| US20220017920A1 (en) | 2018-11-21 | 2022-01-20 | Umoja Biopharma, Inc. | Multicistronic vector for surface engineering lentiviral particles |
| CN109722420A (zh) * | 2019-03-15 | 2019-05-07 | 江苏艾洛特医药研究院有限公司 | 一种改良嵌合抗原受体t细胞的制备及其应用 |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3154281A1 (en) | 2019-10-16 | 2021-04-22 | Andrew Scharenberg | Retroviral vector for universal receptor therapy |
| AU2021213735A1 (en) | 2020-01-30 | 2022-09-22 | Umoja Biopharma, Inc. | Bispecific transduction enhancer |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| EP4247963A1 (en) | 2020-11-20 | 2023-09-27 | Umoja Biopharma, Inc. | Vector system for delivery of multiple polynucleotides and uses thereof |
| AU2022212952A1 (en) | 2021-01-27 | 2023-08-10 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
| CN112941039A (zh) * | 2021-02-01 | 2021-06-11 | 南京大学 | 一种新型类囊泡溶瘤病毒及其在制备抗肿瘤药物上的应用 |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| AU2023212736A1 (en) * | 2022-01-25 | 2024-08-01 | Sunshine Lake Pharma Co., Ltd. | Viral vector and application thereof |
| WO2023198828A1 (en) | 2022-04-13 | 2023-10-19 | Universitat Autònoma De Barcelona | Treatment of neuromuscular diseases via gene therapy that expresses klotho protein |
| WO2023225569A1 (en) | 2022-05-17 | 2023-11-23 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| TW202434735A (zh) | 2022-11-04 | 2024-09-01 | 美商烏莫賈生物製藥股份有限公司 | 展示黏著分子融合的顆粒 |
| TW202434621A (zh) | 2022-11-04 | 2024-09-01 | 美商優莫佳生物製藥有限公司 | 多核苷酸構築體及相關病毒載體及方法 |
| KR20250121163A (ko) | 2022-11-04 | 2025-08-11 | 우모자 바이오파마 인코포레이티드 | 융합 분자를 디스플레이하는 렌티바이러스 입자 및 이의 용도 |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| WO2024179465A1 (zh) * | 2023-02-27 | 2024-09-06 | 上海君赛生物科技有限公司 | 表达膜结合细胞因子的肿瘤浸润淋巴细胞 |
| WO2024223847A1 (en) * | 2023-04-27 | 2024-10-31 | Miltenyi Biotec B.V. & Co. KG | Pseudotyped retroviral vector particle with anti-cd3 display |
| EP4713467A1 (en) | 2023-05-15 | 2026-03-25 | Umoja Biopharma, Inc. | Lentiviral delivery of anti-cd20 chimeric antigen receptors |
| CN116496417B (zh) * | 2023-06-27 | 2023-10-10 | 北京市肿瘤防治研究所 | 含有膜型il7的融合蛋白及t细胞 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
| AU2024353718A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| WO2025072257A1 (en) * | 2023-09-25 | 2025-04-03 | Kelonia Therapeutics, Inc. | Compositions for treating cancer |
| AU2024353243A1 (en) | 2023-09-25 | 2026-04-09 | Kelonia Therapeutics, Inc. | Antigen binding polypeptides |
| WO2025090978A1 (en) | 2023-10-26 | 2025-05-01 | Cargo Therapeutics, Inc. | Modified immune effector cells |
| WO2025149068A1 (zh) * | 2024-01-10 | 2025-07-17 | 深圳市济因生物科技有限公司 | 一种病毒颗粒及其制备方法与应用 |
| WO2025231174A1 (en) | 2024-04-30 | 2025-11-06 | Umoja Biopharma, Inc. | Manufacturing viral particles |
| WO2025235604A1 (en) | 2024-05-08 | 2025-11-13 | Umoja Biopharma, Inc. | Fusion protein for use as immune cell engager |
| WO2025235862A1 (en) | 2024-05-10 | 2025-11-13 | Inndura Therapeutics Inc. | A modified immune cell receptor comprising a target-binding domain and the extracellular domain of cd16a |
| WO2026052028A1 (zh) * | 2024-09-05 | 2026-03-12 | 深圳市济因生物科技有限公司 | 一种制备表达car的t细胞的方法及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994027643A1 (en) * | 1993-06-01 | 1994-12-08 | Targeted Genetics Corporation | Envelope fusion vectors for use in gene delivery |
| CA2224907A1 (en) * | 1995-07-25 | 1997-02-13 | Introgene B.V. | Methods and means for targeted gene delivery |
| EP1601331A4 (en) | 2003-03-07 | 2007-09-05 | Univ Utah Res Found | IL-2 TRANSMEMBRANE CONSTRUCTS |
| EP1769078A1 (en) * | 2004-07-01 | 2007-04-04 | VIRxSYS Corporation | Vector packaging cell line |
| WO2006063974A2 (en) * | 2004-12-13 | 2006-06-22 | Cytos Biotechnology Ag | Il-15 antigen arrays and uses thereof |
| WO2007095201A2 (en) | 2006-02-15 | 2007-08-23 | The Regents Of The University Of California | Pseudotyped retroviral vectors and methods of use thereof |
| US8293685B2 (en) | 2007-07-26 | 2012-10-23 | The Regents Of The University Of California | Methods for enhancing bacterial cell display of proteins and peptides |
| GB0920775D0 (en) * | 2009-11-26 | 2010-01-13 | King S College | Cells |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| GB201415344D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Protein |
| GB201614093D0 (en) | 2016-08-17 | 2016-09-28 | Autolus Ltd | Vector |
| GB201910651D0 (en) | 2019-07-25 | 2019-09-11 | Autolus Ltd | Virus-like particle |
-
2015
- 2015-03-02 GB GB201503500A patent/GB201503500D0/en not_active Ceased
-
2016
- 2016-03-01 AU AU2016227474A patent/AU2016227474A1/en not_active Abandoned
- 2016-03-01 BR BR112017018251-3A patent/BR112017018251A2/pt not_active Application Discontinuation
- 2016-03-01 ES ES16709502T patent/ES2877398T5/es active Active
- 2016-03-01 WO PCT/GB2016/050537 patent/WO2016139463A1/en not_active Ceased
- 2016-03-01 MX MX2017010553A patent/MX2017010553A/es unknown
- 2016-03-01 JP JP2017545941A patent/JP6695347B2/ja active Active
- 2016-03-01 EP EP21171660.0A patent/EP3904523A1/en active Pending
- 2016-03-01 KR KR1020177027017A patent/KR20180002602A/ko not_active Abandoned
- 2016-03-01 SG SG11201706721PA patent/SG11201706721PA/en unknown
- 2016-03-01 CA CA2977472A patent/CA2977472A1/en not_active Abandoned
- 2016-03-01 RU RU2017133854A patent/RU2017133854A/ru not_active Application Discontinuation
- 2016-03-01 CN CN201680013282.6A patent/CN107406860A/zh active Pending
- 2016-03-01 US US15/554,499 patent/US10954530B2/en active Active
- 2016-03-01 EP EP16709502.5A patent/EP3265570B2/en active Active
-
2017
- 2017-08-03 IL IL253820A patent/IL253820B/en active IP Right Grant
- 2017-08-30 CL CL2017002199A patent/CL2017002199A1/es unknown
-
2020
- 2020-03-23 JP JP2020050861A patent/JP2020092722A/ja not_active Withdrawn
-
2021
- 2021-03-04 US US17/192,561 patent/US11814641B2/en active Active
-
2023
- 2023-02-28 JP JP2023029559A patent/JP2023060000A/ja not_active Withdrawn
-
2024
- 2024-12-19 US US18/987,004 patent/US20250388929A1/en active Pending
-
2025
- 2025-12-03 JP JP2025227149A patent/JP2026026312A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506983A5 (https=) | ||
| RU2017133854A (ru) | Вектор | |
| Kolchinsky et al. | Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops | |
| Yang et al. | Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers | |
| Mebatsion et al. | A CXCR4/CD4 pseudotype rhabdovirus that selectively infects HIV-1 envelope protein-expressing cells | |
| Egelhofer et al. | Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides | |
| Yang et al. | Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins | |
| EP2583974B1 (en) | Pseudotyping of foamy viruses | |
| JP2019509063A5 (https=) | ||
| JP2021502799A (ja) | レトロウイルスベクター | |
| Kayman et al. | The hypervariable domain of the murine leukemia virus surface protein tolerates large insertions and deletions, enabling development of a retroviral particle display system | |
| US20240124848A1 (en) | Stable lentivirus packaging cell line and preparation method therefor | |
| Swanstrom et al. | Sequencing the biology of entry: the retroviral env gene | |
| US20240401077A1 (en) | Koala retrovirus envelope gylcoproteins and uses thereof | |
| US20240190988A1 (en) | Novel chimeric antigen receptors and libraries | |
| Vahlenkamp et al. | A single amino acid substitution in the transmembrane envelope glycoprotein of feline immunodeficiency virus alters cellular tropism | |
| Muratori et al. | Lentivirus-based virus-like particles as a new protein delivery tool | |
| Buffa et al. | A single administration of lentiviral vectors expressing either full-length human immunodeficiency virus 1 (HIV-1) HXB2 Rev/Env or codon-optimized HIV-1JR-FL gp120 generates durable immune responses in mice | |
| CN106755109A (zh) | 一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体 | |
| Steidl et al. | Coreceptor Switch of [MLV (SIVagm)] pseudotype vectors by V3-loop exchange | |
| JP2014528729A (ja) | ウイルスベクター精製システム | |
| Tsukahara et al. | Characterization of envelope glycoprotein mutants for human T-cell leukemia virus type 1 infectivity and immortalization | |
| WO2024220597A2 (en) | Digital droplet based assay for detecting replication competent lentiviral vector | |
| EP1739180A1 (en) | T cell line-based packaging cell line for the production of retroviruses by enriching of CD3 expressing cells | |
| Sparacio et al. | Inter-retroviral fusion mediated by human immunodeficiency virus or murine leukemia virus glycoproteins: independence of cellular membranes and membrane vesicles |